Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial
Nishita Singh,Mohammed A. Almekhlafi,Fouzi Bala,Ayoola Ademola,Shelagh B. Coutts,Yan Deschaintre,Houman Khosravani,Brian Buck,Ramana Appireddy,Francois Moreau,Gord Gubitz,Aleksander Tkach,Luciana Catanese,Dar Dowlatshahi,George Medvedev,Jennifer Mandzia,Aleksandra Pikula,Jai Jai Shankar,Esseeddeegg Ghrooda,Alexandre Y. Poppe,Heather Williams,Thalia S. Field,Alejandro Manosalva,Muzaffar M. Siddiqui,Atif Zafar,Oje Imoukhoude,Gary Hunter,Michel Shamy,Andrew M. Demchuk,Brian L. Claggett,Michael D. Hill,Tolulope T. Sajobi,Richard H. Swartz,Bijoy K. Menon
DOI: https://doi.org/10.1161/strokeaha.123.044267
IF: 10.17
2023-10-08
Stroke
Abstract:Stroke, Ahead of Print. BACKGROUND:The AcT (Alteplase Compared to Tenecteplase) randomized controlled trial showed that tenecteplase is noninferior to alteplase in treating patients with acute ischemic stroke within 4.5 hours of symptom onset. The effect of time to treatment on clinical outcomes with alteplase is well known; however, the nature of this relationship is yet to be described with tenecteplase. We assessed whether the association of time to thrombolysis treatment with clinical outcomes in patients with acute ischemic stroke differs by whether they receive intravenous tenecteplase versus alteplase.METHODS:Patients included were from AcT, a pragmatic, registry-linked, phase 3 randomized controlled trial comparing intravenous tenecteplase to alteplase in patients with acute ischemic stroke. Eligible patients were >18 years old, with disabling neurological deficits, presenting within 4.5 hours of symptom onset, and eligible for thrombolysis. Primary outcome was modified Rankin Scale score 0 to 1 at 90 days. Safety outcomes included 24-hour symptomatic intracerebral hemorrhage and 90-day mortality rates. Mixed-effects logistic regression was used to assess the following: (a) the association of stroke symptom onset to needle time; (b) door (hospital arrival) to needle time with outcomes; and (c) if these associations were modified by type of thrombolytic administered (tenecteplase versus alteplase), after adjusting for age, sex, baseline stroke severity, and site of intracranial occlusion.RESULTS:Of the 1538 patients included in this analysis, 1146 (74.5%; 591 tenecteplase and 555 alteplase) presented within 3 hours versus 392 (25.5%; 196: TNK and 196 alteplase) who presented within 3 to 4.5 hours of symptom onset. Baseline patient characteristics in the 0 to 3 hours versus 3- to 4.5-hour time window were similar, except patients in the 3- to 4.5-hour window had lower median baseline National Institutes of Health Stroke Severity Scale (10 versus 7, respectively) and lower proportion of patients with large vessel occlusion on baseline CT angiography (26.9% versus 18.7%, respectively). Type of thrombolytic agent (tenecteplase versus alteplase) did not modify the association between continuous onset to needle time (Pinteraction=0.161) or door-to-needle time (Pinteraction=0.972) and primary clinical outcome. Irrespective of the thrombolytic agent used, each 30-minute reduction in onset to needle time was associated with a 1.8% increase while every 10 minutes reduction in door-to-needle time was associated with a 0.2% increase in the probability of achieving 90-day modified Rankin Scale score 0 to 1, respectively.CONCLUSIONS:The effect of time to tenecteplase administration on clinical outcomes is like that of alteplase, with faster administration resulting in better clinical outcomes.REGISTRATION:URL:https://classic.clinicaltrials.gov; Unique identifier: NCT03889249.
peripheral vascular disease,clinical neurology